Structure | Chemical Name | CAS | MF |
|
N-ALPHA-FMOC-N-OMEGA-(2,2,4,6,7-PENTAMETHYLDIHYDRO-BENZOFURAN-5-SULFONYL)-L-ARGININE 4-BENZYLOXYBENZYL ESTER POLYMER BOUND
|
|
|
|
N-alpha-t-Butyloxycarbonyl-L-leucine p-nitrophenyl ester
|
|
C17H24N2O6
|
|
N-alpha-Cbz-L-lysine
|
2212-75-1
|
C14H20N2O4
|
|
Glycocholic acid
|
475-31-0
|
C26H43NO6
|
|
BOC-D-Arg(Tos)-OH
|
61315-61-5
|
C18H28N4O6S
|
|
N-ALPHA-T-BOC-ETHYLMERCAPTO-L-CYSTEINE DICYCLOHEXYLAMMONIUM SALT
|
25461-00-1
|
C22H42N2O4S2
|
|
N-ALPHA-TRITYL-O-BENZYL-L-HOMOSERINE DIETHYLAMINE
|
1272755-09-5
|
C34H40N2O3
|
|
N-ALPHA-BENZOYL-L-HISTIDINE
|
5354-94-9
|
C13H13N3O3
|
|
N(alpha)-((acetylthio)acetyl)-phenylalanyl-prolyl-arginine chloromethyl ketone
|
115290-74-9
|
C25H35ClN6O5S
|
|
N-ALPHA-T-BUTYLOXYCARBONYL-L-HOMOTYROSINE DICYCLOHEXYLAMINE
|
|
C15H21NO5
|
|
N-alpha-Allyloxycarbonyl-N-epsilon-(9-fluorenylmethyloxycarbonyl)-L-lysine
|
186350-56-1
|
C25H28N2O6
|
|
NALPHA-TERT-BUTOXYCARBONYL-L-TERT-LEUCINE
|
|
C11H21NO4
|
|
N(alpha)-(2-naphthylsulfonylglycyl)-4-oxamidinophenylalanine piperidide
|
117855-58-0
|
C27H31N5O5S
|
|
N(alpha)-(2-naphthylsulfonylglycyl)-4-guanidinomethylphenylalaninepiperidide
|
109273-51-0
|
C28H34N6O4S
|
|
N-alpha-t-Butyloxycarbonyl-beta-(2-benzothiazolyl)-L-alanine
|
1263045-14-2
|
C15H18N2O4S
|
|
N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-in-t-butyloxycarbonyl-L-dihydrotryptophan
|
854890-33-8
|
C31H32N2O6
|
|
N-ALPHA-TERT-BUTOXYCARBONYL-L-PHENYLGLYCINE
|
|
C13H17NO4
|
|
N-alpha-Boxycarbonyl-L-propargylglycine
|
|
C13H13NO4
|
|
N(alpha)-acetylglycyllysyl methyl ester
|
10236-44-9
|
C11H21N3O4
|
|
N(alpha)-tosylarginine-4-nitroanilide
|
36186-55-7
|
|
|
NALPHA-TERT-BUTOXYCARBONYL-L-ASPARTIC ACID
|
|
C9H15NO6
|
|
N-ALPHA-T-BUTYLOXYCARBONYL-L-3-IODO-TYROSINE
|
|
C14H18INO5
|
|
NALPHA-TERT-BUTOXYCARBONYL-3-(2-THIENYL)-L-ALANINE
|
|
C12H17NO4S
|
|
Name Reactions and Reagents In Organic Synthesis
|
|
|
|
N(alpha)--fluorenylmethyloxycarbonylamino-4N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)butyric acid
|
|
|
|
N-ALPHA-TERT-BUTYLOXYCARBONYL-(S)-AZEPIN-2-CARBOXYLIC ACID
|
|
|
|
N-ALPHA-TERT-BUTOXYCARBONYL-D-NORLEUCINE
|
|
C11H21NO4
|
|
NALPHA-TERT-BUTOXYCARBONYL-3-(4-THIAZOLYL)-D-ALANINE
|
|
C11H16N2O4S
|
|
N-alpha-Methyl-L-aspartic acid -t-butyl ester hydrochloride
|
|
C9H18ClNO4
|
|
N-alpha-t-Butyloxycarbonyl-N-gamma-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl]-L-2,3-diaminopropionic acid
|
|
C19H30N2O6
|
|
N-alpha-t-Butyloxycarbonyl-gamma-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl]-D-2,4-diaminobutyric acid
|
|
C19H30N2O6
|
|
N-alpha-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-N-gamma-(9-fluorenylmethyloxycarbonyl)-L-ornithine
|
|
C30H34N2O6
|
|
N-alpha-t-Butyloxycarbonyl-N-beta-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl]-L-2,4-diaminobutyric acid
|
|
C18H28N2O6
|
|
N-alpha-(9-Fluorenylmethyloxycarbonyl)-D-Lys[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-OH
|
|
C34H42N2O6
|
|
N-alpha-t-Butoxycarbonyl-L-alpha--diaminopropionic acid -alpha-methyl ester hydrochloride (Boc-Dap-methoxy hydrochloride)
|
|
C9H19ClN2O4
|
|
N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-gamma[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-L-ornithine
|
|
C33H40N2O6
|
|
N-ALPHA-CBZ-GLYCINE N-METHOXY-N-METHYLAMIDE
|
121505-94-0
|
C12H16N2O4
|
|
N-ALPHA-T-BUTYLOXYCARBONYL-DIPROPYLGLYCINE DICYCLOHEXYLAMINE
|
|
C13H25NO4
|
|
N-ALPHA-TRITYL-D-HOMOSERINE DIETHYLAMMONIUM SALT
|
|
C27H34N2O3
|
|
N-ALPHA-T-BUTYLOXYCABONYL-N-ALPHA-METHYL-L-ISOLEUCINE
|
|
C18H29NO5
|
|
N-alpha-Cbz-D-2-4-diaminobutanoic acid
|
70882-66-5
|
C12H16N2O4
|
|
Fmoc-Asn(Trt)-OH
|
132388-59-1
|
C38H32N2O5
|
|
N(alpha)-dansyl-N(omega)-1,N(6)-etheno-ADP-ribosylarginine methyl ester
|
104257-22-9
|
C36H48N10O17P2S
|
|
3-(3-(N-(alpha-methylbenzyl)aminomethyl)pyrrolidiny)-5-((2-oxooxazolidinyl)methyl)indole
|
|
C25H30N4O2
|
|
N(alpha)-acetyl-epsilon-(2-propenal)lysine
|
99124-74-0
|
C11H18N2O4
|
|
3-(N-alpha-methylbenzyl)aminomethyl-1-(2-(5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl)ethyl)pyrrolidine
|
|
|
|
N-ALPHA-TERT-BUTOXYCARBONYL-L-PROLINOL
|
|
C10H19NO3
|
|
NALPHA-9-Fluorenylmethoxycarbonyl-L-pipecolinic acid
|
84000-01-1
|
C21H21NO4
|
|
N-(A-METHYL-4-NITROBENZYLIDENE)BENZYLAMINE
|
|
C15H14N2O2
|
|
N(a)-Methylhistamine, DiHCl
|
|
|
|
N-[A-METHYL-4-(METHYLSULPHONYL)BENZYL]-N-(TETRAHYDROFURFURYL)BENZAMIDE
|
|
C21H25NO4S
|
|
N-(A-METHYLBENZYL)-1-AMINOBENZOTRIAZOLE
|
105026-59-3
|
C13H12N4
|
|
N-(A-METHYLBENZYLIDENE)ISOPROPYLAMINE
|
6907-73-9
|
C11H15N
|
|
6α-Naloxol Hydrochloride
|
34520-00-8
|
C19H24ClNO4
|
|
Naloxone-d5 3-β-D-Glucuronide
|
|
C25H29NO10
|
|
Naloxone-3-sulfate Sodium Salt
|
156047-22-2
|
C19H22NNaO7S
|
|
6β-Naloxol-d5 Hydrochloride
|
|
C19H24ClNO4
|
|
Naloxone 2,3,4-Tri-O-acetyl-β-D-glucuronic Acid Methyl Ester
|
|
C32H37NO13
|
|
Naloxol 6-b-D-glucuronide
|
|
C25H31NO10
|
|
Naloxegol
|
854601-70-0
|
C34H53NO11
|
|
Naloxone N-Oxide
|
112242-14-5
|
C19H21NO5
|
|
NALOXOL-3-GLUCURONIDE
|
24326-39-4
|
C25H31NO10
|
|
Naloxone
|
465-65-6
|
C19H21NO4
|
|
NALOXONE-D5
|
1261079-38-2
|
C19H21NO4
|
|
NALOXONE-3-GLUCURONIDE
|
|
C25H29NO10
|
|
Naloxone-3,14-diacetate
|
50510-01-5
|
C23H25NO6
|
|
Naloxol 6--D-Glucuronide
|
|
C25H31NO10
|
|
NALOXONE METHIODIDE
|
93302-47-7
|
C20H24NO4.I
|
|
Naloxone-d5 3-Methyl Ether
|
1261082-21-6
|
C20H23NO4
|
|
NALOXONE, [N-ALLYL 2,3-3H]
|
|
C19H18NO4T3
|
|
NALOXONE HYDROCHLORIDE DIHYDRATE MM(CRM STANDARD)
|
|
|
|
NALOXONE IMPURITY A4,5-ALPHA-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE (NOROXYMORPHONE) EPN(CRM STANDARD)
|
|
|
|
NALP1 (NACHT-, LRR- and PYD-Containing Protein 1, DEFCAP, NAC, CARD7, Caspase Recruitment Domain 7) (A)
|
|
|
|
Naloxone 3-b-D-Glucuronide
|
22135-79-1
|
C25H29NO10
|
|
NALOXONE HYDROCHLORIDE BP STANDARD(CRM STANDARD)
|
|
|
|
NALOXONE HYDROCHLORIDE ASSAY STANDARD BP(CRM STANDARD)
|
|
|
|
NALP3 (NACHT-, LRR- and PYD-Containing Protein 3, Cryopyrin, Cold Autoinflammatory Syndrome 1 Protein, PYPAF1, PYRIN-Containing APAF1-like Protein 1, CIAS1) (A)
|
|
|
|
NALOXONE HYDROCHLORIDE EPN(CRM STANDARD)
|
|
|
|
NALOXONE MM(CRM STANDARD)
|
|
|
|
NALP3 (NACHT-, LRR- and PYD-Containing Protein 3, Cryopyrin, Cold Autoinflammatory Syndrome 1 Protein, PYPAF1, PYRIN-Containing APAF1-like Protein 1, CIAS1)
|
|
|
|
naloxone-6-spirohydantoin
|
87872-71-7
|
C21H23N3O5
|
|
naloxone receptor
|
|
|
|
naloxazone
|
73674-85-8
|
C19H23N3O3
|
|
naloxazine
|
71786-91-9
|
C19H25N3O3
|
|
NALOXONAZINE DIHYDROCHLORIDE
|
82824-01-9
|
C38H44Cl2N4O6
|
|
NALP1, NT (NACHT-, LRR- and PYD-Containing Protein 1, DEFCAP, NAC, CARD7, Caspase Recruitment Domain 7)
|
|
|
|
NALOXONE BENZOYLHYDRAZONE
|
119630-94-3
|
C26H27N3O4
|
|
NALOXONE USP(CRM STANDARD)
|
|
|
|
naloxone-3-O-methyl-oxime
|
|
|
|
NALOXONE FLUORESCEIN
|
88641-41-2
|
C40H34N4O8S
|
|
NALOXONE BENZOYLHYDRAZONE
|
|
C26H27N3O4
|
|
Naloxone hydrochloride dihydrate
|
51481-60-8
|
C19H26ClNO6
|
|
Naloxone hydrochloride
|
357-08-4
|
C19H22ClNO4
|
|
Naloxyindole
|
126580-45-8
|
C25H24N2O3
|
|
Naloxone methylbromide
|
|
|
|
NALP1 protein
|
|
|
|
NB.BPU10I
|
|
|
|
NBC1 (HCO3 Cotransporters 1, pNBC) A
|
|
|
|
NBC1 (HCO3 Cotransporters 1)
|
|
|
|
NBC3 (HCO3 Cotransporters 3) C
|
|
|